J&J Bounces Back: An Interview with Ashley McEvoy


A wide-ranging discussion with J&J’s EVP and Worldwide Chairman of Medical Devices on how she plans to get Johnson & Johnson’s medtech mojo back.

Fifteen years ago, when Johnson & Johnson launched its historic $20 billion-plus offer for Guidant Corp., many medtech industry executives quietly cheered, if only because, they argued, it suggested the value that the healthcare giant was willing to place on medical devices.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: